Health care giant Johnson & Johnson (
) saw its earnings estimates lowered on Friday by analysts at
The firm said it lowered its estimates for JNJ through 2011,
citing a longer-than-expected closure of the company's
Washington-based over-the-counter drug facility. The company has
issued a recall on some of its Benedryl and Tylenol products, after
customer complaints about a moldy smell that can cause nausea and
Still, UBS maintained its "Buy" rating and $75 price target for
the stock. That target represents a nearly 26% upside to the
stock's Thursday closing price of $59.60.
Johnson & Johnson shares rose 37 cents, or +0.6%, in
premarket trading Friday.
The Bottom Line
We have been recommending shares of JNJ since Oct.8, when the stock
was trading at $60.71. The company has a 3.62% dividend yield,
based on last night's closing stock price of $59.60.
Johnson & Johnson (
) is a "recommended" dividend stock, holding a Dividend.com DARS™
Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the
Best Dividend Stocks
, as well as a detailed explanation of
our ratings system here
Created by Dividend.com